A Two Year Follow up Study of Group Metacognitive Therapy for Depression in Norway
|Toril Dammen1*, Costas Papageorgiou2 and Adrian Wells3,4|
|1Department of Behavioural Sciences in Medicine, Institute of Basic Medical Sciences, Oslo, Norway|
|2The Priory Hospital, Altrincham, Rappax Road, Hale, Altrincham, Cheshire WA15 0NX, UK|
|3University of Manchester, School of Psychological Sciences, Rawnsley Building, Manchester Royal Infirmary Oxford Road, Manchester M13 9WL, UK|
|4Manchester Mental Health and Social Care, NHS Trust, UK|
|*Corresponding Author :||Toril Dammen
Department of Behavioural Sciences in Medicine
Institute of Basic Medical Sciences
Post Box 1111, Blindern
0317 Oslo, Norway
E-mail: [email protected]
|Received March 15, 2016; Accepted April 25, 2016; Published April 28, 2016|
|Citation: Dammen T, Papageorgiou C, Wells A (2016) A Two Year Follow up Study of Group Metacognitive Therapy for Depression in Norway. J Depress Anxiety 5:227. doi:10.4172/2167-1044.1000227|
|Copyright: © 2016 Dammen T, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.|
Objective: Preliminary data support the implementation of individual metacognitive therapy (MCT) for depression and recently published data indicate that group MCT in the treatment of depression is effective and well-accepted. This study examined 12 and 24 months follow up of patients treated with group MCT. We conducted a one and two year follow-up of an open trial of group MCT.
Method: Ten patients who were consecutively referred by general practitioners to a specialist psychiatric practice in Norway participated in an open trial of the effects and feasibility associated with group MCT for depression. All of the patients met the DSM-IV criteria for major depressive disorder (MDD) and were followed up for 6 months, one and two year. The primary symptom outcome measure was severity of depression whilst secondary outcome measures included levels of anxiety, rumination, and metacognitive beliefs. We also assessed recovery rates and changes in comorbid Axis I and Axis II diagnoses at one and two year follow up.
Result: Large clinically significant improvements across all measures that were detected at post-treatment were maintained at one year and two year follow up. Based on objectively defined recovery criteria, 70% of the patients were classified as recovered at 1 year and 80% at 2 year follow up.
Conclusion: These preliminary data indicate that group MCT in the treatment of depression had sustained efficacy after one and two years, beyond what has been typically reported for cognitive behavioral therapy (CBT).